Blueprint Medicines Corp BPMC
Last Updated: Jul 17, 12:00 AM·BE
BPMC Shariah Compliance
Screening Methodology: AAOIFI
As of July 2026, Blueprint Medicines Corp is classified as halal.
HALAL
Report Source: 2025 1st Quarter Report
Blueprint Medicines Corp. Stock Analysis BPMC
Germany Health Care Mid Cap Report: Blueprint Medicines Corp. is a precision therapy company, which engages in the provision of medicines for people with cancer and blood disorders. The company is headquartered in Cambridge, Massachusetts and currently employs 649 full-time employees. The company went IPO on 2015-04-30. The firm invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The firm delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. The company has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. The company is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. The company is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases.
Read More Blueprint Medicines Corp (BPMC) Chart
Key Statistics of Blueprint Medicines Corp (BPMC)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
€129.35Volume
2.93MP/E Ratio (TTM)
-52 Week Range
Market Cap
7.16BAvg. Volume
4.40MDividend Yield
-Financial Metrics & Statements of Blueprint Medicines Corp (BPMC)
Super Investors Invested in Blueprint Medicines Corp (BPMC)
FAQ's for Blueprint Medicines Corp (BPMC)
- As of July 2026, Blueprint Medicines Corp BPMC is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Blueprint Medicines Corp using these criteria to determine its compliance status.
- Muslim investors may consider investing in Blueprint Medicines Corp if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Blueprint Medicines Corp by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Blueprint Medicines Corp may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Blueprint Medicines Corp on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.